Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma

Jee Hung Kim, Hyung Soon Park, Su Jin Heo, Sang Kyum Kim, Jung Woo Han, Kyoo Ho Shin, Seung Hyun Kim, Hyuk Hur, Kyung Sik Kim, Young Deuk Choi, Sunghoon Kim, Young Han Lee, Jin Suck Suh, Joong Bae Ahn, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha, Hyo Song Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: We retrospectively investigated the treatment outcomes of second-line treatment with pazopanib or gemcitabine/docetaxel in patients with advanced soft tissue sarcoma (STS). Methods: Ninety-one patients who were treated with pazopanib or gemcitabine/docetaxel for advanced STS between 1995 and 2015 were analyzed. Results: Forty-six and 45 patients received pazopanib and gemcitabine/docetaxel, respectively. The median progression-free survival for the group treated with pazopanib was 4.5 months compared with 3.0 months for the gemcitabine/docetaxel group (p = 0.593). The median overall survival for the group treated with pazopanib was 12.6 months compared with 14.2 months for the gemcitabine/docetaxel group (p = 0.362). The overall response rates (ORRs) were 6.5 and 26.7% in the pazopanib and gemcitabine/docetaxel groups, respectively. The following parameters had ORRs favoring gemcitabine/docetaxel: age ≥50 years (31.6 vs. 2.9%, p = 0.006), histologic grade 1-2 (40.9 vs. 0%, p = 0.001), and poor first-line treatment response (23.3 vs. 3.0%, p = 0.022). Gemcitabine/docetaxel was associated with better ORRs for the following histologic subtypes: leiomyosarcoma (p = 0.624), malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma (p = 0.055), and angiosarcoma (p = 0.182). However, the ORR of synovial sarcoma favored pazopanib (p = 0.99). Conclusions: The efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments after doxorubicin or ifosfamide failure differed among clinical and histologic subgroups and appeared to facilitate a more personalized treatment approach for advanced STS.

Original languageEnglish
Pages (from-to)59-69
Number of pages11
JournalOncology (Switzerland)
Volume96
Issue number2
DOIs
Publication statusPublished - 2019 Feb 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma'. Together they form a unique fingerprint.

  • Cite this

    Kim, J. H., Park, H. S., Heo, S. J., Kim, S. K., Han, J. W., Shin, K. H., Kim, S. H., Hur, H., Kim, K. S., Choi, Y. D., Kim, S., Lee, Y. H., Suh, J. S., Ahn, J. B., Chung, H. C., Noh, S. H., Rha, S. Y., & Kim, H. S. (2019). Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma. Oncology (Switzerland), 96(2), 59-69. https://doi.org/10.1159/000492597